Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Stephen Chia"'
Autor:
Claudia Arce-Salinas, Manuel Ramos-Vázquez, Eun Sook Lee, Jean-Yves Pierga, Kevin Kalinsky, Catherine M. Kelly, Sukhbinder Dhesy-Thind, Miguel Gil-Gil, Edith A. Perez, Jieling Miao, Debasish Tripathy, Priya Rastogi, William E. Barlow, Nan Lin, Stephen Chia, Steven Shak, Daniel F. Hayes, Manuel Ruiz-Borrego, Begoña Bermejo, Jean-Marc Ferrero, Suzette Delaloge, Lori J. Goldstein, Lajos Pusztai, Emilio Alba, Danika L. Lew, Julie R. Gralow, Anne F. Schott, Etienne Brain, Kathy S. Albain, Gabriel N. Hortobagyi, Kyung Hae Jung, Miguel Martín, Funda Meric-Bernstam, Priyanka Sharma
Publikováno v:
N Engl J Med
NEW ENGLAND JOURNAL OF MEDICINE
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
NEW ENGLAND JOURNAL OF MEDICINE
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
BACKGROUND: The recurrence score based on the 21-gene breast-cancer assay has been clinically useful in predicting a chemotherapy benefit in hormone-receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative, axillary lymph-node
Autor:
Mehrnoosh Pauls, Stephen Chia
Publikováno v:
Current oncology (Toronto, Ont.). 29(7)
Breast cancer (BC) is the most common malignancy among women in Canada. Adjuvant treatment in early BC can reduce the risk of BC recurrence. Historically, the decision for adjuvant chemotherapy for early BC was made only based on clinical and tumour
Publikováno v:
Breast Cancer Research and Treatment. 184:755-762
The optimal time interval from neoadjuvant chemotherapy (NAC) to surgery in patients with breast cancer has not been established. We investigated whether different time intervals impact the rate of pathologic complete response (pCR), disease free sur
Publikováno v:
Curr Oncol
Current Oncology
Volume 27
Issue 3
Pages 5907-270
Current Oncology
Volume 27
Issue 3
Pages 5907-270
Studies in the adjuvant setting suggest that the timing of breast cancer diagnosis, surgery, and chemotherapy might affect outcomes. In the neoadjuvant setting, data exploring whether expeditious neoadjuvant chemotherapy (nac) after diagnosis improve
Autor:
Caroline Speers, Lovedeep Gondara, J Sun, Stephen Chia, Caroline A. Lohrisch, Nathalie LeVasseur, Rekha M. Diocee
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 146:529-536
Achieving a pathologic complete response (pCR) has been associated with improved long-term outcomes in clinical trials. However, the benefit of achieving pCR across subtypes and its prognostic effect on real-world outcomes has not been well described
Autor:
Neelima Denduluri, Marc Buyse, Robert Šeparović, Bent Ejlertsen, Stephen Chia, Gunter von Minckwitz, Alshad S. Lalani, Michael Gnant, Frankie A. Holmes, John A. Smith, Vernon Harvey, Bo Zhang, Hiroji Iwata, Janine Mansi, Beverly Moy, Sung-Bae Kim, Nicholas J. Robert, Yining Ye, Carlos H. Barrios, Erik Jakobsen, Arlene Chan, Suzette Delaloge, Miguel Martin, Lisa D. Eli, Z Tomasevic, Graydon Harker
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-9 (2019)
Chia, S K L, Martin, M, Holmes, F A, Ejlertsen, B, Delaloge, S, Moy, B, Iwata, H, von Minckwitz, G, Mansi, J, Barrios, C H, Gnant, M, Tomašević, Z, Denduluri, N, Šeparović, R, Kim, S-B, Jakobsen, E H, Harvey, V, Robert, N, Smith, J, Harker, G, Zhang, B, Eli, L D, Ye, Y, Lalani, A S, Buyse, M & Chan, A 2019, ' PIK3CA alterations and benefit with neratinib : analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial ', Breast Cancer Research, vol. 21, 39 . https://doi.org/10.1186/s13058-019-1115-2
Breast Cancer Research : BCR
Chia, S K L, Martin, M, Holmes, F A, Ejlertsen, B, Delaloge, S, Moy, B, Iwata, H, von Minckwitz, G, Mansi, J, Barrios, C H, Gnant, M, Tomašević, Z, Denduluri, N, Šeparović, R, Kim, S-B, Jakobsen, E H, Harvey, V, Robert, N, Smith, J, Harker, G, Zhang, B, Eli, L D, Ye, Y, Lalani, A S, Buyse, M & Chan, A 2019, ' PIK3CA alterations and benefit with neratinib : analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial ', Breast Cancer Research, vol. 21, 39 . https://doi.org/10.1186/s13058-019-1115-2
Breast Cancer Research : BCR
Background: Neratinib is an irreversible pan-HER tyrosine kinase inhibitor that inhibits PI3K/Akt and MAPK signaling pathways after HER2 receptor activation. The ExteNET study showed that neratinib significantly improved 5-year invasive disease-free
Autor:
Richard D. Gelber, Vernon Harvey, Barbara Walley, E Abdi, Stephen Chia, Gini F. Fleming, Prudence A. Francis, Jacquie Chirgwin, Marco Colleoni, Anita Giobbie-Hurder, Andre van der Westhuizen, Angelo Di Leo, Alan S. Coates, Muhammed Salim, Juerg Bernhard, Harold J. Burstein, Rafat H Ansari, Meredith M. Regan, Aron Goldhirsch, Olivia Pagani, Weixiu Luo, Karin Ribi
Publikováno v:
Breast cancer research and treatment. 181(2)
PURPOSE Sexual dysfunction is an important concern of premenopausal women with early breast cancer. We investigated predictors of sexual problems in two randomized controlled trials. METHODS A subset of patients enrolled in TEXT and SOFT completed gl
Autor:
J Sun, Stephen Chia
Publikováno v:
British Journal of Cancer
There is a lack of sufficient evidence-based data defining the optimal adjuvant systemic therapies in older women. Recommendations are mainly based on retrospective studies, subgroup analyses within larger randomised trials and expert opinion. Treatm
Autor:
Walter Yip, Huaqi Li, Kaylie-Anne Willemsma, Nathalie LeVasseur, Christine Simmons, Caroline F. Illmann, Lovedeep Gondara, Stephen Chia
Publikováno v:
Clinical breast cancer. 19(6)
Although neoadjuvant chemotherapy (NACT) has been established as a standard for medically fit patients with locally advanced breast cancer, there has been renewed interest in utilizing neoadjuvant endocrine therapy (NET) for women with estrogen recep
Autor:
Sandra M. Swain, James L. Wade, Stephen Chia, Charles E. Geyer, Louis Fehrenbacher, Janice M. Walshe, Gamini S. Soori, Eleftherios P. Mamounas, Hanna Bandos, D. Lawrence Wickerham, Jong-Hyeon Jeong, Soonmyung Paik, Edward C. McCarron, Mark L. Graham, Shaker R. Dakhil, Adam Brufsky, Priya Rastogi, Barry C. Lembersky, Norman Wolmark, Thomas E. Seay
Publikováno v:
The Lancet. Oncology. 20(1)
The optimal duration of extended therapy with aromatase inhibitors in patients with postmenopausal breast cancer is unknown. In the NSABP B-42 study, we aimed to determine whether extended letrozole treatment improves disease-free survival after 5 ye